[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR042890A1 - Metodo de tratamiento del ojo seco con una composicion oftalmica que contiene un compuesto macrolido - Google Patents

Metodo de tratamiento del ojo seco con una composicion oftalmica que contiene un compuesto macrolido

Info

Publication number
AR042890A1
AR042890A1 ARP040100110A ARP040100110A AR042890A1 AR 042890 A1 AR042890 A1 AR 042890A1 AR P040100110 A ARP040100110 A AR P040100110A AR P040100110 A ARP040100110 A AR P040100110A AR 042890 A1 AR042890 A1 AR 042890A1
Authority
AR
Argentina
Prior art keywords
composition containing
dry eye
ophthalmic composition
compound
macrolid
Prior art date
Application number
ARP040100110A
Other languages
English (en)
Inventor
R Ueno
Original Assignee
Sucampo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Pharmaceuticals Inc filed Critical Sucampo Pharmaceuticals Inc
Publication of AR042890A1 publication Critical patent/AR042890A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Métodos para el tratamiento del ojo seco, los cuales comprenden la administración de una cantidad efectiva de una composición oftálmica que contiene un compuesto macrólido, tal como tacrólimo, a un paciente que tiene un puntaje de Schimer inferior o igual a siete milímetros por cada cinco minutos y/o un puntaje de queratitis punteada superficial de al menos dos.
ARP040100110A 2003-01-16 2004-01-16 Metodo de tratamiento del ojo seco con una composicion oftalmica que contiene un compuesto macrolido AR042890A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44038803P 2003-01-16 2003-01-16

Publications (1)

Publication Number Publication Date
AR042890A1 true AR042890A1 (es) 2005-07-06

Family

ID=32713549

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100110A AR042890A1 (es) 2003-01-16 2004-01-16 Metodo de tratamiento del ojo seco con una composicion oftalmica que contiene un compuesto macrolido

Country Status (3)

Country Link
US (1) US20040198763A1 (es)
AR (1) AR042890A1 (es)
WO (1) WO2004062669A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1406700A1 (en) * 2001-07-06 2004-04-14 Sucampo AG Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
BRPI0608152A2 (pt) 2005-02-09 2009-11-10 Macusight Inc formulações para tratamento ocular
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
AU2007212271B2 (en) 2006-02-09 2012-11-01 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
JP5506378B2 (ja) 2006-03-23 2014-05-28 参天製薬株式会社 血管透過性に関連する疾患または病気のための製剤および方法
US8536190B2 (en) * 2007-01-30 2013-09-17 Allergan, Inc. Treating unwanted ocular conditions using an ascomycin macrolactam
WO2013022238A2 (ko) * 2011-08-05 2013-02-14 (주)제노텍 트리사이클로 당화 유도체 화합물, 그 제조방법 및 타크롤리무스 당화 유도체를 포함하는 면역억제용 약제학적 조성물
KR101318151B1 (ko) 2011-09-26 2013-10-15 (주) 제노텍 타크롤리무스 당화 유도체를 포함하는 면역억제용 약제학적 조성물
EP4247367A4 (en) 2020-11-23 2024-10-16 Sight Sciences Inc FORMULATIONS AND METHODS FOR TREATING EYE CONDITIONS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0163035B1 (ko) * 1989-07-05 1998-12-01 후지사와 도모키치로 외용 수성 액체 조성물
CA2054983A1 (en) * 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
WO1992019278A1 (en) * 1991-04-26 1992-11-12 Kurume University Use of macrolide compounds for eye diseases
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
US5457182A (en) * 1994-02-15 1995-10-10 Merck & Co., Inc. FK-506 cytosolic binding protein, FKBP12.6
US5952371A (en) * 1996-10-16 1999-09-14 Merck & Co., Inc. Triterpene derivatives with immunosuppressant activity
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
US6376517B1 (en) * 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
KR20020015316A (ko) * 1999-04-30 2002-02-27 수캄포 아게 안구 건조증 치료를 위한 매크로라이드 화합물의 용도
US6489335B2 (en) * 2000-02-18 2002-12-03 Gholam A. Peyman Treatment of ocular disease
AR033151A1 (es) * 2001-04-12 2003-12-03 Sucampo Pharmaceuticals Inc Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares
EP1458405A1 (en) * 2001-11-21 2004-09-22 Sucampo AG Use of fk506 and analogues for treating allergic diseases

Also Published As

Publication number Publication date
WO2004062669A1 (en) 2004-07-29
US20040198763A1 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
AR042890A1 (es) Metodo de tratamiento del ojo seco con una composicion oftalmica que contiene un compuesto macrolido
AR121843A2 (es) Formulación oftálmica y método para mejorar la presbicia
PE20171439A1 (es) Metodos para tratar infecciones por el virus filoviridae
AR054371A1 (es) Metodos y composiciones para manejo de desordenes psicoticos
CO5640121A2 (es) Un metodo de tratamiento de un trastorno de la ansiedad
EA200702126A1 (ru) Амилин и агонисты амилина для лечения психиатрических заболеваний и расстройств
BR112018069251A2 (pt) métodos de intervenção precoce para prevenir ou melhorar a toxicidade
EA201190219A1 (ru) Способы и композиции для лечения ишемических состояний и состояний, связанных с функцией митохондрий
PA8680701A1 (es) Derivados de oxindol
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
CO6331301A2 (es) Combinaciones y metodos para administracion subcutanea de inmunoglobulina y hialuronidasa
MX2010003548A (es) Metodos para el tratamiento de padecimientos neurologicos autoinmunes con ciclofosfamida.
BR112013000027A2 (pt) tratamento de distúrbios cognitivos
NO20083036L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av depresjon
AR052955A1 (es) Producto de combinacion de o- desmetilvanlafaxina y bazedoxifeno y usos del mismo
MX2021015992A (es) Azacitidina en combinación con venetoclax, gilteritinib, midostaurina u otros compuestos para tratamiento de leucemia o síndrome mielodisplásico.
UY28255A1 (es) Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del veger
BRPI0509363A (pt) método para aumentar a eficácia preservativa de uma composição, composição oftálmica, método de tratamento de uma condição oftálmica e processo para produzir uma composição oftálmica
AR091724A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica
PA8597501A1 (es) Derivados azabiciclicos de piridiloximetilo y bencisoxazol
MX2022010093A (es) Tafoxiparina para el tratamiento de la preeclampsia.
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
NI201100148A (es) Uso de deferiprona para el tratamiento y la prevención de trastornos oculares relacionados con hierro.
BR112017025189A2 (pt) composição e usos da mesma
WO2019126695A3 (en) Methods and pharmaceutical compositions for treating candida auris in blood

Legal Events

Date Code Title Description
FB Suspension of granting procedure